Production (Stage)
Cyclacel Pharmaceuticals, Inc.
CYCC
$0.3371
-$0.075-18.20%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -81.00K | -3.05M | -1.96M | -3.26M | -2.95M |
| Total Depreciation and Amortization | -- | 1.00K | 1.00K | 2.00K | 2.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.68M | 93.00K | 102.00K | 173.00K | 187.00K |
| Change in Net Operating Assets | -4.84M | 1.60M | -1.21M | -2.00K | 2.27M |
| Cash from Operations | -3.25M | -1.36M | -3.07M | -3.08M | -483.00K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3.89M | 1.61M | -- | 6.21M | -- |
| Repurchase of Common Stock | -- | -- | -1.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -248.00K | -- | -- | 79.00K | -79.00K |
| Cash from Financing | 3.65M | 1.61M | -1.00K | 6.29M | -79.00K |
| Foreign Exchange rate Adjustments | -86.00K | -102.00K | 50.00K | -3.00K | -18.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 313.00K | 155.00K | -3.02M | 3.20M | -580.00K |